MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Allogene Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

1.15 -1.71

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.13

Max

1.21

Schlüsselkennzahlen

By Trading Economics

Einkommen

206K

-60M

EPS

-0.28

Gewinnspanne

272,450

Angestellte

226

EBITDA

-302K

-56M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+637.82% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.2M

258M

Vorheriger Eröffnungskurs

2.86

Vorheriger Schlusskurs

1.15

Nachrichtenstimmung

By Acuity

50%

50%

113 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Juli 2025, 15:29 UTC

Wichtige Markttreiber

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7. Juli 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7. Juli 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Juli 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7. Juli 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Juli 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7. Juli 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Juli 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7. Juli 2025, 21:34 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Juli 2025, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. Juli 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7. Juli 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7. Juli 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7. Juli 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7. Juli 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Juli 2025, 16:53 UTC

Ergebnisse

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7. Juli 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Juli 2025, 16:05 UTC

Akquisitionen, Fusionen, Übernahmen

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. Juli 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7. Juli 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. Juli 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7. Juli 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7. Juli 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7. Juli 2025, 15:14 UTC

Akquisitionen, Fusionen, Übernahmen

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7. Juli 2025, 15:00 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Completes Acquisition of Efimosfermin

7. Juli 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7. Juli 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7. Juli 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Peer-Vergleich

Kursveränderung

Allogene Therapeutics Inc Prognose

Kursziel

By TipRanks

637.82% Vorteil

12-Monats-Prognose

Durchschnitt 8.78 USD  637.82%

Hoch 14 USD

Tief 4 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Allogene Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

11

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

1.18 / 1.69Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

113 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.